Personalized melanoma vaccine shows promise in stage 3 trial
Interim trial results show a personalized Moderna vaccine, used with Keytruda, extends cancer-free time in high-risk melanoma patients.
The Full Story
A plain summary built from the channels that reported this story.
Interim results from a stage 3 trial of a personalized melanoma vaccine have shown it can extend the time patients remain cancer-free after surgery. The vaccine, made by Moderna, is given in combination with the drug Keytruda, made by Merck, to patients with high-risk melanoma. The findings, presented as interim data, showed a longer period without cancer recurrence and a reduced risk of the disease spreading to other organs, compared with the drug alone.
Cancer Research UK described the results as showing "signs of early positive encouragement", while some commentators urged caution until full data are available. One commentator called it a breakthrough, saying vaccines could protect against the recurrence of one of the deadliest cancers. Shares in both Moderna and Merck rose on Wall Street following the announcement.
The trial is still in its final stage, and further findings are awaited. The vaccine is personalized for each patient, and is administered after surgery. The study is seen as significant because it is a personalized treatment, and the results suggest it may reduce the risk of melanoma spreading to other organs.
On screen
Stills are sampled automatically at 60-second intervals. Where shown, the still is the nearest available frame from the relevant broadcast segment and is included to show what was on screen during that part of the broadcast. A still may not correspond to the exact second of a quoted phrase.
Key Claims
Claims reported during this story's coverage, mapped by channel. Ordered by how many channels carried each claim.
| Claim | BBC News | BBC One |
|---|---|---|
| A personalised Moderna vaccine is given after surgery with Merck's Keytruda. | ||
| A personalized cancer vaccine was developed by Moderna. | ||
| Cancer Research UK said the findings are encouraging. | ||
| The trial showed longer cancer-free survival and reduced risk of spread for high-risk melanoma patients. | ||
| A clinical trial is testing whether CAR-T immunotherapy is safe for people with multiple sclerosis. | · | |
| Newman is the first patient in Sheffield and the seventh in an international clinical trial. | · | |
| Share prices for Moderna and Merck rose after the announcement. | · | |
| The vaccine trial is at stage 3, the final phase, and the findings are interim. | · |
Channel Perspectives
What each channel focused on, with key quotes.
This channel focused on the cautious optimism around the trial, with health editor Hugh Pym stressing that these are interim findings from a stage 3 trial and that full data are not yet available. It highlighted Cancer Research UK's positive but measured response, and noted one commentator's breakthrough claim.
- “Well Clive it's looking that way but these are interim findings from this stage 3 trial”
- “one commentator has said this is a breakthrough showing a vaccine can protect against the recurrence of one of the deadliest cancers”
This channel presented the same report as BBC ONE West — BBC News, with identical wording. It emphasized the interim nature of the results and the cautious stance of some commentators, while noting the potential significance of a personalized vaccine.
- “Well Clive it's looking that way but these are interim findings from this stage 3 trial”
- “one commentator has said this is a breakthrough showing a vaccine can protect against the recurrence of one of the deadliest cancers”
This channel took a more upbeat tone, highlighting the market reaction with share prices rising for both Moderna and Merck on Wall Street. It also stressed the personalized nature of the vaccine and included a commentator's breakthrough claim, while still noting the preliminary nature of the findings.
- “the significance here is that it's a personalized vaccine for individual patients”
- “that hasn't stopped share prices going up pretty significantly for both companies on Wall Street tonight”
- “a commentator saying tonight that it is a breakthrough showing that vaccines can protect against the recurrence of one of the deadliest cancers”
Broadcast Timeline
News broadcasts tracked for this story, in time order.